Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists

Abstract

The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability—hypersensitivity—hyperaesthesia—dissociative phenomena—etc). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.

1 - 81 . (canceled) 
     
     
         82 . A pharmaceutical composition for treating a psychotic disorder comprising:
 (a) pipamperone,   (b) a D2 receptor antagonist,   and a pharmaceutically acceptable carrier,   wherein the composition provides a daily dose of 5-15 mg pipamperone.   
     
     
         83 . The pharmaceutical composition of  claim 82  for treating schizophrenia. 
     
     
         84 . The pharmaceutical composition of  claim 82 , wherein the composition provides a daily dose of 5 mg pipamperone. 
     
     
         85 . The pharmaceutical composition of  claim 83 , wherein the composition provides a daily dose of 5 mg pipamperone. 
     
     
         86 . The pharmaceutical composition of  claim 82 , wherein the composition provides a daily dose of 10 mg pipamperone. 
     
     
         87 . The pharmaceutical composition of  claim 83 , wherein the composition provides a daily dose of 10 mg pipamperone. 
     
     
         88 . The pharmaceutical composition of  claim 82 , wherein the composition provides a daily dose of 15 mg pipamperone. 
     
     
         89 . The pharmaceutical composition of  claim 83 , wherein the composition provides a daily dose of 15 mg pipamperone. 
     
     
         90 . The pharmaceutical composition of  claim 82 , wherein pipamperone is in the form of a pharmaceutically acceptable salt. 
     
     
         91 . The pharmaceutical composition of  claim 83 , wherein pipamperone is in the form of a pharmaceutically acceptable salt. 
     
     
         92 . The pharmaceutical composition of  claim 82 , wherein said D2 receptor antagonist is in the form of a pharmaceutically acceptable salt. 
     
     
         93 . The pharmaceutical composition of  claim 83 , wherein said D2 receptor antagonist is in the form of a pharmaceutically acceptable salt. 
     
     
         94 . A pharmaceutical composition comprising:
 (a) 5-15 mg pipamperone,   (b) a D2 receptor antagonist,   and a pharmaceutically acceptable carrier.   
     
     
         95 . The pharmaceutical composition of  claim 94 , wherein pipamperone
 and said D2 receptor antagonist are present in an amount effective to treat a psychotic disorder.   
     
     
         96 . The pharmaceutical composition of  claim 94 , wherein pipamperone and said D2 receptor antagonist are present in an amount effective to treat schizophrenia. 
     
     
         97 . The pharmaceutical composition of  claim 94 , wherein pipamperone is present in a dose of 5 mg. 
     
     
         98 . The pharmaceutical composition of  claim 94 , wherein pipamperone is present in a dose of 10 mg. 
     
     
         99 . The pharmaceutical composition of  claim 94 , wherein pipamperone is present in a dose of 15 mg. 
     
     
         100 . The pharmaceutical composition of  claim 94 , wherein pipamperone is in the form of a pharmaceutically acceptable salt. 
     
     
         101 . The pharmaceutical composition of  claim 94 , wherein said D2 receptor antagonist is in the form of a pharmaceutically acceptable salt.